WO2001062736A1 - Aryl fused azapolycyclic compounds - Google Patents

Aryl fused azapolycyclic compounds Download PDF

Info

Publication number
WO2001062736A1
WO2001062736A1 PCT/IB2001/000153 IB0100153W WO0162736A1 WO 2001062736 A1 WO2001062736 A1 WO 2001062736A1 IB 0100153 W IB0100153 W IB 0100153W WO 0162736 A1 WO0162736 A1 WO 0162736A1
Authority
WO
WIPO (PCT)
Prior art keywords
dodeca
pentadeca
aza
tetraene
methyl
Prior art date
Application number
PCT/IB2001/000153
Other languages
English (en)
French (fr)
Inventor
Paige Roanne Palmer Brooks
Jotham Wadsworth Coe
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to HU0204580A priority Critical patent/HU229482B1/hu
Priority to EP01953630A priority patent/EP1259489B1/en
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Priority to BR0108610-3A priority patent/BR0108610A/pt
Priority to EEP200200475A priority patent/EE200200475A/xx
Priority to DZ013328A priority patent/DZ3328A1/fr
Priority to CA002401229A priority patent/CA2401229C/en
Priority to KR10-2002-7011140A priority patent/KR100537976B1/ko
Priority to PL01365163A priority patent/PL365163A1/xx
Priority to APAP/P/2002/002604A priority patent/AP1860A/en
Priority to SK1204-2002A priority patent/SK12042002A3/sk
Priority to IL15063901A priority patent/IL150639A0/xx
Priority to SI200130584T priority patent/SI1259489T1/sl
Priority to NZ519973A priority patent/NZ519973A/en
Priority to EA200200716A priority patent/EA005316B1/ru
Priority to DE60120366T priority patent/DE60120366T2/de
Priority to MXPA02008311A priority patent/MXPA02008311A/es
Priority to JP2001562518A priority patent/JP2003524002A/ja
Priority to AU28748/01A priority patent/AU784081B2/en
Priority to UA2002075792A priority patent/UA74813C2/uk
Publication of WO2001062736A1 publication Critical patent/WO2001062736A1/en
Priority to IS6459A priority patent/IS2293B/is
Priority to BG106908A priority patent/BG65891B1/bg
Priority to IL150639A priority patent/IL150639A/en
Priority to NO20024042A priority patent/NO323608B1/no
Priority to HRP20020700 priority patent/HRP20020700A2/hr
Priority to HK03103024A priority patent/HK1050894A1/xx
Priority to AU2005234671A priority patent/AU2005234671B2/en
Priority to CY20061101011T priority patent/CY1105301T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/24—Camphidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PCT/IB2001/000153 2000-02-25 2001-02-08 Aryl fused azapolycyclic compounds WO2001062736A1 (en)

Priority Applications (27)

Application Number Priority Date Filing Date Title
DE60120366T DE60120366T2 (de) 2000-02-25 2001-02-08 Aryl-kondensierte azopolycyclische Verbindungen
EA200200716A EA005316B1 (ru) 2000-02-25 2001-02-08 Арилконденсированные азаполициклические соединения
BR0108610-3A BR0108610A (pt) 2000-02-25 2001-02-08 Compostos azapolicìclicos condensados com arila
EP01953630A EP1259489B1 (en) 2000-02-25 2001-02-08 Aryl fused azapolycyclic compounds
DZ013328A DZ3328A1 (US07205300-20070417-C00003.png) 2000-02-25 2001-02-08
CA002401229A CA2401229C (en) 2000-02-25 2001-02-08 Aryl fused azapolycyclic compounds
KR10-2002-7011140A KR100537976B1 (ko) 2000-02-25 2001-02-08 아릴 융합된 아자폴리시클릭 화합물
PL01365163A PL365163A1 (en) 2000-02-25 2001-02-08 Aryl fused azapolycyclic compounds
APAP/P/2002/002604A AP1860A (en) 2000-02-25 2001-02-08 Aryl fused azapolycyclic compounds.
SK1204-2002A SK12042002A3 (sk) 2000-02-25 2001-02-08 Azapolycyklické zlúčeniny s anelovanou arylskupinou
MXPA02008311A MXPA02008311A (es) 2000-02-25 2001-02-08 Compuestos azapoliciclicos condensados con arilo.
SI200130584T SI1259489T1 (sl) 2000-02-25 2001-02-08 Z arilom kondenzirane azapoliciklicne spojine
NZ519973A NZ519973A (en) 2000-02-25 2001-02-08 Aryl fused azapolycyclic compounds that bind neuronal nicotinic acetylcholine specific receptor sites
HU0204580A HU229482B1 (en) 2000-02-25 2001-02-08 Aryl fused azapolycyclic compounds
EEP200200475A EE200200475A (et) 2000-02-25 2001-02-08 Arüülkondenseerunud asapolütsüklilised ühendid
IL15063901A IL150639A0 (en) 2000-02-25 2001-02-08 Aryl fused azapolycyclic compounds
JP2001562518A JP2003524002A (ja) 2000-02-25 2001-02-08 アリール縮合アザ多環状化合物
AU28748/01A AU784081B2 (en) 2000-02-25 2001-02-08 Aryl fused azapolycyclic compounds
UA2002075792A UA74813C2 (en) 2000-02-25 2001-08-02 Azapolycyclic compounds condensated with aryl
IS6459A IS2293B (is) 2000-02-25 2002-07-05 Arýl sambrædd asapólýsýklísk efnasambönd
BG106908A BG65891B1 (bg) 2000-02-25 2002-07-05 Кондензирани с арил азаполициклени съединения
IL150639A IL150639A (en) 2000-02-25 2002-07-08 Enantiomers of azapolitic compounds fused to aryl, medicinal preparations containing them and their use in the preparation of medicines
NO20024042A NO323608B1 (no) 2000-02-25 2002-08-23 Aryl-fusjonerte azapolysykliske forbindelser, anvendelse derav og farmasoytisk sammensetning.
HRP20020700 HRP20020700A2 (en) 2000-02-25 2002-08-26 Aryl fused azapolycyclic compounds
HK03103024A HK1050894A1 (en) 2000-02-25 2003-04-29 Aryl fused azapolycyclic compounds
AU2005234671A AU2005234671B2 (en) 2000-02-25 2005-11-18 Aryl fused azapolycyclic compounds
CY20061101011T CY1105301T1 (el) 2000-02-25 2006-07-21 Αρυλοσυμπυκνωμενες αζαπολυκυκλικες ενωσεις

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/514,002 2000-02-25
US09/514,002 US6605610B1 (en) 1997-12-31 2000-02-25 Aryl fused azapolycyclic compounds

Publications (1)

Publication Number Publication Date
WO2001062736A1 true WO2001062736A1 (en) 2001-08-30

Family

ID=24045406

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/000153 WO2001062736A1 (en) 2000-02-25 2001-02-08 Aryl fused azapolycyclic compounds

Country Status (40)

Country Link
US (3) US6605610B1 (US07205300-20070417-C00003.png)
EP (2) EP1259489B1 (US07205300-20070417-C00003.png)
JP (1) JP2003524002A (US07205300-20070417-C00003.png)
KR (1) KR100537976B1 (US07205300-20070417-C00003.png)
CN (1) CN1263745C (US07205300-20070417-C00003.png)
AP (1) AP1860A (US07205300-20070417-C00003.png)
AT (2) ATE453643T1 (US07205300-20070417-C00003.png)
AU (2) AU784081B2 (US07205300-20070417-C00003.png)
BG (1) BG65891B1 (US07205300-20070417-C00003.png)
BR (1) BR0108610A (US07205300-20070417-C00003.png)
CA (1) CA2401229C (US07205300-20070417-C00003.png)
CR (1) CR6726A (US07205300-20070417-C00003.png)
CU (1) CU23148A3 (US07205300-20070417-C00003.png)
CY (1) CY1105301T1 (US07205300-20070417-C00003.png)
CZ (1) CZ303203B6 (US07205300-20070417-C00003.png)
DE (2) DE60140965D1 (US07205300-20070417-C00003.png)
DK (2) DK1259489T3 (US07205300-20070417-C00003.png)
DZ (1) DZ3328A1 (US07205300-20070417-C00003.png)
EA (1) EA005316B1 (US07205300-20070417-C00003.png)
EE (1) EE200200475A (US07205300-20070417-C00003.png)
ES (2) ES2263640T3 (US07205300-20070417-C00003.png)
GE (1) GEP20053454B (US07205300-20070417-C00003.png)
HK (1) HK1050894A1 (US07205300-20070417-C00003.png)
HR (1) HRP20020700A2 (US07205300-20070417-C00003.png)
HU (1) HU229482B1 (US07205300-20070417-C00003.png)
IL (2) IL150639A0 (US07205300-20070417-C00003.png)
IS (1) IS2293B (US07205300-20070417-C00003.png)
MA (1) MA26875A1 (US07205300-20070417-C00003.png)
MX (1) MXPA02008311A (US07205300-20070417-C00003.png)
NO (1) NO323608B1 (US07205300-20070417-C00003.png)
NZ (1) NZ519973A (US07205300-20070417-C00003.png)
OA (1) OA12181A (US07205300-20070417-C00003.png)
PL (1) PL365163A1 (US07205300-20070417-C00003.png)
PT (1) PT1259489E (US07205300-20070417-C00003.png)
RS (1) RS51123B (US07205300-20070417-C00003.png)
SI (1) SI1259489T1 (US07205300-20070417-C00003.png)
SK (1) SK12042002A3 (US07205300-20070417-C00003.png)
UA (1) UA74813C2 (US07205300-20070417-C00003.png)
WO (1) WO2001062736A1 (US07205300-20070417-C00003.png)
ZA (1) ZA200206768B (US07205300-20070417-C00003.png)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037329A1 (en) * 2001-10-31 2003-05-08 Pfizer Products Inc. Nicotinic acetylcholine receptor agonists in the treatment of restless legs syndrome
WO2003045967A1 (en) * 2001-11-30 2003-06-05 Pfizer Products Inc. Aryl fused azapolycyclic compounds
WO2003045437A1 (en) * 2001-11-30 2003-06-05 Pfizer Products Inc. Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
WO2005007630A2 (en) * 2003-07-21 2005-01-27 Pfizer Products Inc. Aryl fused azapolycyclic compounds
WO2005063296A2 (en) * 2003-12-23 2005-07-14 Pfizer Products Inc. Therapeutic combination for cognition enhancement and psychotic disorders
WO2006006071A1 (en) * 2004-07-07 2006-01-19 Pfizer Products Inc. Resolution of an aryl-fused azapolycyclic compound
WO2008060487A3 (en) * 2006-11-09 2008-08-07 Pfizer Prod Inc Polymorphs of nicotinic intermediates
WO2009034431A2 (en) 2007-09-10 2009-03-19 Pfizer Inc. Controlled-release dosage forms for varenicline
WO2009065872A2 (en) * 2007-11-20 2009-05-28 Medichem, S.A. Improved processes for the synthesis of varenicline l-tartrate
EP2226074A2 (en) 2006-12-12 2010-09-08 Abbott Laboratories Pharmaceutical compositions and their methods of use
WO2010151524A1 (en) * 2009-06-22 2010-12-29 Teva Pharmaceutical Industries Ltd Solid states forms of varenicline salts and processes for preparation thereof
US8039620B2 (en) 2008-05-22 2011-10-18 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline L-tartrate
EP2392345A2 (en) 2002-07-18 2011-12-07 Cytos Biotechnology AG Hapten-carrier conjugates comprising virus like particles and uses thereof
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US8546401B2 (en) 2007-12-07 2013-10-01 AbbVie Deutschland GmbH & Co. KG 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressin-dependent diseases
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US8703775B2 (en) 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
US8703774B2 (en) 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
US8815868B2 (en) 2006-12-30 2014-08-26 Abbott Gmbh & Co. Kg Substituted oxindole derivatives and their use as vasopressin receptor ligands
US9023854B2 (en) 2007-12-07 2015-05-05 AbbVie Deutschland GmbH & Co. KG 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressin-dependent diseases
US9040568B2 (en) 2009-05-29 2015-05-26 Abbvie Inc. Pharmaceutical compositions for the treatment of pain
US9463190B2 (en) 2008-03-31 2016-10-11 University Of South Florida Methods of treating disease-induced ataxia and non-ataxic imbalance
WO2018160043A1 (ko) 2017-03-03 2018-09-07 주식회사 씨티씨바이오 바레니클린 또는 이의 약학적으로 허용가능한 염의 포접 복합체를 포함하는 구강 투여용 제제
CN115322105A (zh) * 2021-05-11 2022-11-11 江苏润安制药有限公司 一种合成艾拉莫德关键中间体的方法
EP4084797A4 (en) * 2020-01-03 2024-02-21 Blue Oak Pharmaceuticals Inc COMPOUNDS AND COMPOSITIONS FOR TREATING CNS DISEASES

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122008000038I1 (de) * 1997-12-31 2008-11-13 Pfizer Prod Inc Arylkondensierte azapolycyclische derivate
KR100551183B1 (ko) * 2001-04-20 2006-02-13 화이자 프로덕츠 인크. 1,3-치환 인덴 및 아릴-융합 아자폴리시클릭 화합물의제조 방법
EP1554041B1 (en) * 2002-10-22 2012-05-23 EMD Millipore Corporation Multi-sided immersion formation of composite structures and method
WO2004048318A1 (en) * 2002-11-25 2004-06-10 Pfizer Products Inc. Improved process for the preparation of 1,3-substituted indenes
WO2004063164A1 (en) * 2003-01-15 2004-07-29 Pfizer Products Inc. Process for the preparation of aryl fused polycyclic lactams
WO2004103372A1 (en) * 2003-05-20 2004-12-02 Pfizer Products Inc. Pharmaceutical compositions of varenicline
WO2004108725A1 (en) * 2003-06-04 2004-12-16 Pfizer Products Inc. Preparation of substituted quinoxalines from the dianline with 2,3-dihydroxy-1,4-dioxane
CA2541752C (en) 2003-10-14 2012-01-03 Xenoport, Inc. Crystalline form of gamma-aminobutyric acid analog
KR20070098942A (ko) * 2005-02-24 2007-10-05 화이자 프로덕츠 인코포레이티드 고순도의 치환된 퀴녹살린의 제조 방법
BRPI0710914A2 (pt) * 2006-04-24 2011-09-27 Pfizer Prod Inc forma de dosagem e método para o tratamento de dependência, adição e supressão de nicotina, em particular para uso na terapia para parar de fumar
US20090062257A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched varenicline
WO2009155403A2 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Processes for the preparation of varenicline and intermediates thereof
WO2010005643A1 (en) * 2008-07-10 2010-01-14 Teva Pharmaceutical Industries Ltd. Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
US8314235B2 (en) * 2008-09-01 2012-11-20 Actavis Group Ptc Ehf Process for preparing varenicline, varenicline intermediates, pharmaceutically acceptable salts thereof
EP2396327A1 (en) 2009-02-11 2011-12-21 Sunovion Pharmaceuticals Inc. Histamine h3 inverse agonists and antagonists and methods of use thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999035131A1 (en) * 1997-12-31 1999-07-15 Pfizer Products Inc. Aryl fused azapolycyclic compounds
WO1999055680A1 (en) * 1998-04-29 1999-11-04 Pfizer Products Inc. Aryl fused azapolycyclic compounds
EP0955301A2 (en) * 1998-04-27 1999-11-10 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylchloline receptors
WO2000044755A1 (en) * 1999-01-29 2000-08-03 Abbott Laboratories Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
WO2000045846A1 (fr) * 1999-02-02 2000-08-10 Sanofi-Synthelabo Compositions pharmaceutiques contenant de la nicotine ou un ligand des recepteurs nicotiniques et un inhibiteur de la monamine oxydase et leur application dans le sevrage tabagique
EP1078637A2 (en) * 1999-08-27 2001-02-28 Pfizer Products Inc. Composition for the treatment and prevention of nicotine addiction containing a nicotine receptor agonist and an anti-depressant or anti-anxiety drug

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471503A (en) 1967-05-05 1969-10-07 Mcneilab Inc 1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols
WO2002074050A2 (en) * 2001-03-19 2002-09-26 Sloan Kettering Institute For Cancer Research Asymmetric synthesis of (s, s, r)-(-)-actinonin and its analogs and uses therefor
EP1648872A2 (en) * 2003-07-21 2006-04-26 Pfizer Products Inc. Aryl fused azapolycyclic compounds
US8123947B2 (en) 2007-10-22 2012-02-28 Baxter International Inc. Priming and air removal systems and methods for dialysis

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999035131A1 (en) * 1997-12-31 1999-07-15 Pfizer Products Inc. Aryl fused azapolycyclic compounds
EP0955301A2 (en) * 1998-04-27 1999-11-10 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylchloline receptors
WO1999055680A1 (en) * 1998-04-29 1999-11-04 Pfizer Products Inc. Aryl fused azapolycyclic compounds
WO2000044755A1 (en) * 1999-01-29 2000-08-03 Abbott Laboratories Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
WO2000045846A1 (fr) * 1999-02-02 2000-08-10 Sanofi-Synthelabo Compositions pharmaceutiques contenant de la nicotine ou un ligand des recepteurs nicotiniques et un inhibiteur de la monamine oxydase et leur application dans le sevrage tabagique
EP1078637A2 (en) * 1999-08-27 2001-02-28 Pfizer Products Inc. Composition for the treatment and prevention of nicotine addiction containing a nicotine receptor agonist and an anti-depressant or anti-anxiety drug

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PAUL H MAZZOCHI ET AL: "Synthesis and pharmacological activity of 2,3,4,5-tetrahydro-1,5-meth ano-1H-3-benzazepines", JOURNAL OF MEDICINAL CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 22, no. 4, 1979, pages 455 - 457, XP002090422, ISSN: 0022-2623 *

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037329A1 (en) * 2001-10-31 2003-05-08 Pfizer Products Inc. Nicotinic acetylcholine receptor agonists in the treatment of restless legs syndrome
WO2003045967A1 (en) * 2001-11-30 2003-06-05 Pfizer Products Inc. Aryl fused azapolycyclic compounds
WO2003045437A1 (en) * 2001-11-30 2003-06-05 Pfizer Products Inc. Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
US6858624B2 (en) 2001-11-30 2005-02-22 Pfizer, Inc. Aryl fused azapolycyclic compounds
US7771748B2 (en) 2001-11-30 2010-08-10 Pfizer Inc Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene
KR100892517B1 (ko) * 2001-11-30 2009-04-10 화이자 프로덕츠 인크. 5,8,14-트리아자테트라시클로[10.3.1.0(2,11).0(4,9)]-헥사데카-2(11)3,5,7,9-펜타엔의 약학 조성물
EP2392345A2 (en) 2002-07-18 2011-12-07 Cytos Biotechnology AG Hapten-carrier conjugates comprising virus like particles and uses thereof
WO2005007630A3 (en) * 2003-07-21 2005-04-28 Pfizer Prod Inc Aryl fused azapolycyclic compounds
WO2005007630A2 (en) * 2003-07-21 2005-01-27 Pfizer Products Inc. Aryl fused azapolycyclic compounds
US9487505B2 (en) 2003-09-30 2016-11-08 AbbVie Deutschland GmbH & Co. KG Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
WO2005063296A2 (en) * 2003-12-23 2005-07-14 Pfizer Products Inc. Therapeutic combination for cognition enhancement and psychotic disorders
WO2005063296A3 (en) * 2003-12-23 2006-04-20 Pfizer Prod Inc Therapeutic combination for cognition enhancement and psychotic disorders
WO2006006071A1 (en) * 2004-07-07 2006-01-19 Pfizer Products Inc. Resolution of an aryl-fused azapolycyclic compound
WO2008060487A3 (en) * 2006-11-09 2008-08-07 Pfizer Prod Inc Polymorphs of nicotinic intermediates
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US9186407B2 (en) 2006-12-12 2015-11-17 Abbvie Inc. Pharmaceutical compositions and their methods of use
EP2226074A2 (en) 2006-12-12 2010-09-08 Abbott Laboratories Pharmaceutical compositions and their methods of use
EP2974727A1 (en) 2006-12-12 2016-01-20 Abbvie Inc. Pharmaceutical compositions and their methods of use
US8859557B2 (en) 2006-12-30 2014-10-14 Abbott Gmbh & Co. Kg Substituted oxindole derivatives and their use as vasopressin receptor ligands
US8815868B2 (en) 2006-12-30 2014-08-26 Abbott Gmbh & Co. Kg Substituted oxindole derivatives and their use as vasopressin receptor ligands
WO2009034431A2 (en) 2007-09-10 2009-03-19 Pfizer Inc. Controlled-release dosage forms for varenicline
WO2009065872A2 (en) * 2007-11-20 2009-05-28 Medichem, S.A. Improved processes for the synthesis of varenicline l-tartrate
WO2009065872A3 (en) * 2007-11-20 2009-11-05 Medichem, S.A. Processes for the synthesis of varenicline l-tartrate
US9403796B2 (en) 2007-12-07 2016-08-02 AbbVie Deutschland GmbH & Co. KG Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
US8703775B2 (en) 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
US8703774B2 (en) 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
US8546401B2 (en) 2007-12-07 2013-10-01 AbbVie Deutschland GmbH & Co. KG 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressin-dependent diseases
US9023854B2 (en) 2007-12-07 2015-05-05 AbbVie Deutschland GmbH & Co. KG 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressin-dependent diseases
US9434713B2 (en) 2007-12-07 2016-09-06 AbbVie Deutschland GmbH & Co. KG 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressin-dependent diseases
US9422264B2 (en) 2007-12-07 2016-08-23 AbbVie Deutschland GmbH & Co. KG Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
US9782404B2 (en) 2008-03-31 2017-10-10 University Of South Florida Methods of treating disease-induced ataxia and non-ataxic imbalance
US9463190B2 (en) 2008-03-31 2016-10-11 University Of South Florida Methods of treating disease-induced ataxia and non-ataxic imbalance
US8039620B2 (en) 2008-05-22 2011-10-18 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline L-tartrate
US9040568B2 (en) 2009-05-29 2015-05-26 Abbvie Inc. Pharmaceutical compositions for the treatment of pain
WO2010151524A1 (en) * 2009-06-22 2010-12-29 Teva Pharmaceutical Industries Ltd Solid states forms of varenicline salts and processes for preparation thereof
US8178537B2 (en) 2009-06-22 2012-05-15 Teva Pharmaceutical Industries Ltd. Solid state forms of varenicline salts and processes for preparation thereof
WO2018160043A1 (ko) 2017-03-03 2018-09-07 주식회사 씨티씨바이오 바레니클린 또는 이의 약학적으로 허용가능한 염의 포접 복합체를 포함하는 구강 투여용 제제
US11266658B2 (en) 2017-03-03 2022-03-08 Ctc Bio, Inc. Preparation, comprising inclusion complex of varenicline or pharmaceutically acceptable salt thereof, for oral administration
EP4084797A4 (en) * 2020-01-03 2024-02-21 Blue Oak Pharmaceuticals Inc COMPOUNDS AND COMPOSITIONS FOR TREATING CNS DISEASES
CN115322105A (zh) * 2021-05-11 2022-11-11 江苏润安制药有限公司 一种合成艾拉莫德关键中间体的方法

Also Published As

Publication number Publication date
DE60120366T2 (de) 2007-07-05
KR20030005209A (ko) 2003-01-17
MXPA02008311A (es) 2002-12-09
AU2005234671B2 (en) 2008-04-17
HK1050894A1 (en) 2003-07-11
AU2874801A (en) 2001-09-03
MA26875A1 (fr) 2004-12-20
US7144882B2 (en) 2006-12-05
EP1619192B1 (en) 2009-12-30
OA12181A (en) 2006-05-09
US7205300B2 (en) 2007-04-17
NO323608B1 (no) 2007-06-18
JP2003524002A (ja) 2003-08-12
BR0108610A (pt) 2002-11-19
BG65891B1 (bg) 2010-04-30
ATE453643T1 (de) 2010-01-15
ES2336800T3 (es) 2010-04-16
US6605610B1 (en) 2003-08-12
EE200200475A (et) 2003-12-15
PL365163A1 (en) 2004-12-27
YU59602A (sh) 2005-06-10
US20030130261A1 (en) 2003-07-10
DK1619192T3 (da) 2010-03-29
AU784081B2 (en) 2006-02-02
CA2401229A1 (en) 2001-08-30
IS6459A (is) 2002-07-05
CN1263745C (zh) 2006-07-12
HRP20020700A2 (en) 2004-12-31
ATE328872T1 (de) 2006-06-15
DE60120366D1 (de) 2006-07-20
IL150639A (en) 2011-10-31
AP1860A (en) 2008-07-02
CZ303203B6 (cs) 2012-05-23
CY1105301T1 (el) 2010-03-03
KR100537976B1 (ko) 2005-12-21
HUP0204580A2 (hu) 2003-04-28
EA005316B1 (ru) 2004-12-30
ES2263640T3 (es) 2006-12-16
SK12042002A3 (sk) 2004-02-03
SI1259489T1 (sl) 2006-10-31
EP1619192A3 (en) 2006-03-22
EP1259489A1 (en) 2002-11-27
NO20024042D0 (no) 2002-08-23
HU229482B1 (en) 2014-01-28
DK1259489T3 (da) 2006-10-09
CA2401229C (en) 2007-10-02
CU23148A3 (es) 2006-06-29
IS2293B (is) 2007-10-15
CZ20022778A3 (cs) 2003-09-17
CN1406227A (zh) 2003-03-26
NO20024042L (no) 2002-10-17
NZ519973A (en) 2004-04-30
EA200200716A1 (ru) 2003-02-27
IL150639A0 (en) 2003-02-12
ZA200206768B (en) 2003-09-23
DE60140965D1 (de) 2010-02-11
BG106908A (bg) 2003-04-30
GEP20053454B (en) 2005-02-25
US20030130260A1 (en) 2003-07-10
AU2005234671A1 (en) 2005-12-15
EP1259489B1 (en) 2006-06-07
HUP0204580A3 (en) 2005-04-28
RS51123B (sr) 2010-10-31
AP2002002604A0 (en) 2002-09-30
CR6726A (es) 2003-10-28
EP1619192A2 (en) 2006-01-25
PT1259489E (pt) 2006-08-31
DZ3328A1 (US07205300-20070417-C00003.png) 2001-08-30
UA74813C2 (en) 2006-02-15

Similar Documents

Publication Publication Date Title
EP1259489B1 (en) Aryl fused azapolycyclic compounds
AU753389C (en) Aryl fused azapolycyclic compounds
WO2002085843A2 (en) Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds
AU2002234836A1 (en) Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 1200200778

Country of ref document: VN

Ref document number: P-596/02

Country of ref document: YU

Ref document number: DZP2002000176

Country of ref document: DZ

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 519973

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2001 106908

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 150639

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/00921/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 28748/01

Country of ref document: AU

Ref document number: 2001953630

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20020516

Country of ref document: UZ

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200200716

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: PV2002-2778

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 12042002

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 2401229

Country of ref document: CA

Ref document number: 018055737

Country of ref document: CN

Ref document number: PA/a/2002/008311

Country of ref document: MX

Ref document number: 6585

Country of ref document: GE

WWE Wipo information: entry into national phase

Ref document number: 1020027011140

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2001 562518

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: P20020700A

Country of ref document: HR

WWP Wipo information: published in national office

Ref document number: 2001953630

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020027011140

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2002-2778

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 519973

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 519973

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 1020027011140

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 2001953630

Country of ref document: EP